Buradasınız

Anasayfa » Content

KRONİK BÖBREK YETMEZLİĞİ HASTALARINDA L-KARNİTİN KULLANIMININ NÖTROFİL KEMİLÜMİNESANS CEVABINA ETKİSİ

THE EFFECT OF L-CARNITINE ON NEUTROPHIL CHEMILUMINESCENCE RESPONSE IN CHRONIC RENAL FAILURE PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Neutrophile abnormalities have been reported in chronic renal failure patients. In this study, the effect of l-carnitine on neutrophile chemiluminescence (CL) response (invitro and invivo) was investigated in patients on hemodialysis. Fifteen hemodialized patients and 15 healthy age matched controls were studied. The zymosan induced oxidative metabolism of phagocytes was assessed by means of luminol dependent CL. Control and patients' neutrophils were isolated and CL were determined after 10 minutes incubation with 0, 25, 50 and 100 nmol/ml l-carnitine. The CL response of neutrophils in patient group (2933+393) was significantly lower than the healthy controls (4496+ 717, p<0.001). Significant increases were found in the neutrophil CL response with 25, 50, 100 nmol/ml l-carnitine concentrations (p<0.001) (3527+459, 4372+561, 4322+636, respectively), but same concentrations of l-carnitine did not cause any change in controls' neutrophils. Patients' neutrophil CL responses were reached to controls' levels when incubated with 50nmol/ml l-carnitine. After the in vitro study, 2xlg/day P.O. l-carnitine were given to these patients for 30 days. At the end of this period, CL response was restudied (4562+560) and found to be significantly increased when compared with the before l-carnitine values(p<0.001). These values were not different from the healthy controls. Our findings indicate that neutrophil CL response is significantly increased by l-carnitine in chronic renal failure patients.
Bookmark/Search this post with
Abstract (Original Language): 
Nötrofil fonksiyon bozuklukları Kronik Böbrek Hastalarında bildirilmiştir. Bu çalışmada biz hemodiyaliz tedavisi gören hastalarda L-karnitinin nötrofil kemilüminesans cevabına (in vitro ve in vivo) etkisini araştırdık. Çalışmaya 15 hemodiyaliz hastası ve 15 sağlıklı kontrol alınmıştır. Nötrofillerin zimozanla uyarılmış oksidatif metabolizması, luminole bağlı kemilüminesans yöntemiyle bakılmıştır. Hasta ve kontrol nötrofilleri izole edildikten sonra 0, 25, 50, 100 nmol/ml L-karnitinle 10 dk inkübasyondan sonra kemilüminesçırts değerleri saptanmıştır. Hasta grubunun nötrofil kemilüminesans cevabı (2933±393) sağlıklı kontrollere göre (4496±717, p<0.001) anlamlı derecede düşük bulunmuştur. 25, 50, 100 nmol/ml L-karnitin konsantrasyonlarında anlamlı derecede (p<0.001) artış gözlendi (3527±459, 4372 ±561, 4322±636). AncakL-karnitin kontrollerde benzer konsantrasyonlarda artış göstermemiştir. Hastaların nötrofil kemilüminesans cevapları kontrollerin seviyesine 50 nmol/ml L-karnitinle inkübe edildiğinde ulaşmıştır. Çalışmanın in vivo bölümünde bu hastalara 2x1g/gün olacak şekilde 30 gün süreyle L-karnitin verilmiştir. Bu sürenin sonunda nötrofil kemilüminesans cevapları tekrar çalışılarak (4562±560) anlamlı bir artış olduğu gözlenmiştir, (p<0.001) Bulduğumuz bu değerler sağlıklı kontrollerden farklı değildir. Bulgularımız göstermiştir ki, kronik böbrek yetmezliği olan hastalarda nötrofil kemilüminesans cevapları anlamlı derecede artmıştır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_310.pdf
  • 3
166-169
  • Turkish

REFERENCES

References: 

1. Malech HL, NauseefWM: Primary inherited defects in neutrophil function. Semin Hematol 1997;34:279-290
2. Yang KD, Hill HR: Neutrophil function disorders: Pathophysiology, prevention and therapy. J Pediatr 1991;119:343-353
3. Hill HR: Biochemical, structural and functional abnormalities of polymorphonuclear leukocytes in the neonate. Pediatr Res 1987;22:371-383
4. Haag-Weber M, Hörl W:Altered cellular host defence in malnutrition and uraemia. Contrib Nephrol
1992;98:105-111
5. Chatenoud L, Jungers P, Descamps-Latscha B: Immunological considerations of the uremic and
dialysed patient. Kidney Int 1994;45:92-96
6. Bartell LL, Hussey JL, Shrago E: Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy. Am J Clin Nutr
1981;34:1314-1320
7. Boehm K, Heims R, Chnstensen ML, Storm M:Carnitine: A review for the pharmacy. Clinician
HospPharm 1993;28:847-850
8. Rebouche CJ, Engel AG: Primary systemic carnitine deficiency: I. Carnitine biosynthesis. Neurology 1980;31:813-818
9. Leino L, Nuutila J, Pelliniemi T, Rajamaki A: Human recombinant GM-CSF selectively primers receptor mediated respiratory burst of neutrophils in vitro.
Immunol Lett 1993;38:26-31
10. Vanholder R, Ringoir S, Dhondt A, Hakim R:
Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study. Kidney Int
1991;39:320-327
11. Ritchey E, Walhn JD, Shah SV: Chemiluminescence and superoxide anion production by leukocytes from chronic hemodialysis patients. Kidney Int 1981;19:349-358
12. Shinetti ML, Mazzini A: Effect of L-carnitine on human
neutrophil activity. Int J Tissue React 1986;8:199-203

Thank you for copying data from http://www.arastirmax.com